TISIDB

Summary
Symbol	PECAM1
Name	platelet/endothelial cell adhesion molecule 1
Aliases	CD31; CD31 antigen; platelet/endothelial cell adhesion molecule; CD31/EndoCAM; GPIIA'; PECA1; PECAM-1; endoC ......
Chromosomal Location	17q23.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cell membrane Single-pass type I membrane protein Note=Cell surface expression on neutrophils is down-regulated upon fMLP or CXCL8/IL8-mediated stimulation. ; SUBCELLULAR LOCATION: Isoform Long: Cell membrane Single-pass type I membrane protein Membrane raft Cell junction Note=Localizes to the lateral border recycling compartment (LBRC) and recycles from the LBRC to the junction in resting endothelial cells. ; SUBCELLULAR LOCATION: Isoform Delta15: Cell junction Note=Localizes to the lateral border recycling compartment (LBRC) and recycles from the LBRC to the junction in resting endothelial cells.
Domain	PF13895 Immunoglobulin domain
Function	Cell adhesion molecule which is required for leukocyte transendothelial migration (TEM) under most inflammatory conditions (PubMed:19342684, PubMed:17580308). Tyr-690 plays a critical role in TEM and is required for efficient trafficking of PECAM1 to and from the lateral border recycling compartment (LBRC) and is also essential for the LBRC membrane to be targeted around migrating leukocytes (PubMed:19342684). Trans-homophilic interaction may play a role in endothelial cell-cell adhesion via cell junctions (PubMed:27958302). Heterophilic interaction with CD177 plays a role in transendothelial migration of neutrophils (PubMed:17580308). Homophilic ligation of PECAM1 prevents macrophage-mediated phagocytosis of neighboring viable leukocytes by transmitting a detachment signal (PubMed:12110892). Promotes macrophage-mediated phagocytosis of apoptotic leukocytes by tethering them to the phagocytic cells; PECAM1-mediated detachment signal appears to be disabled in apoptotic leukocytes (PubMed:12110892). Modulates bradykinin receptor BDKRB2 activation (PubMed:18672896). Regulates bradykinin- and hyperosmotic shock-induced ERK1/2 activation in endothelial cells (PubMed:18672896). Induces susceptibility to atherosclerosis (By similarity). ; FUNCTION: Isoform Delta15: Does not protect against apoptosis.

> Gene Ontology [ TOP ]
Biological Process	GO:0001655 urogenital system development GO:0001822 kidney development GO:0002576 platelet degranulation GO:0003158 endothelium development GO:0006887 exocytosis GO:0006909 phagocytosis GO:0008037 cell recognition GO:0030198 extracellular matrix organization GO:0032835 glomerulus development GO:0043062 extracellular structure organization GO:0045055 regulated exocytosis GO:0045123 cellular extravasation GO:0050900 leukocyte migration GO:0050904 diapedesis GO:0061437 renal system vasculature development GO:0061440 kidney vasculature development GO:0072001 renal system development GO:0072006 nephron development GO:0072009 nephron epithelium development GO:0072010 glomerular epithelium development GO:0072011 glomerular endothelium development GO:0072012 glomerulus vasculature development GO:0072073 kidney epithelium development
Molecular Function	-
Cellular Component	GO:0030141 secretory granule GO:0030659 cytoplasmic vesicle membrane GO:0030667 secretory granule membrane GO:0031091 platelet alpha granule GO:0031092 platelet alpha granule membrane GO:0045121 membrane raft GO:0098589 membrane region GO:0098857 membrane microdomain GO:0099503 secretory vesicle

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04514 Cell adhesion molecules (CAMs) hsa04670 Leukocyte transendothelial migration
Reactome	R-HSA-202733: Cell surface interactions at the vascular wall R-HSA-1474244: Extracellular matrix organization R-HSA-109582: Hemostasis R-HSA-168256: Immune System R-HSA-168249: Innate Immune System R-HSA-216083: Integrin cell surface interactions R-HSA-6798695: Neutrophil degranulation R-HSA-210990: PECAM1 interactions R-HSA-76002: Platelet activation, signaling and aggregation R-HSA-114608: Platelet degranulation R-HSA-418346: Platelet homeostasis R-HSA-432142: Platelet sensitization by LDL R-HSA-76005: Response to elevated platelet cytosolic Ca2+

> KEGG and Reactome Pathway

[ TOP ]

KEGG

hsa04514 Cell adhesion molecules (CAMs)
hsa04670 Leukocyte transendothelial migration

Reactome

R-HSA-202733: Cell surface interactions at the vascular wall
R-HSA-1474244: Extracellular matrix organization
R-HSA-109582: Hemostasis
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-216083: Integrin cell surface interactions
R-HSA-6798695: Neutrophil degranulation
R-HSA-210990: PECAM1 interactions
R-HSA-76002: Platelet activation, signaling and aggregation
R-HSA-114608: Platelet degranulation
R-HSA-418346: Platelet homeostasis
R-HSA-432142: Platelet sensitization by LDL
R-HSA-76005: Response to elevated platelet cytosolic Ca2+

Summary
Symbol	PECAM1
Name	platelet/endothelial cell adhesion molecule 1
Aliases	CD31; CD31 antigen; platelet/endothelial cell adhesion molecule; CD31/EndoCAM; GPIIA'; PECA1; PECAM-1; endoC ......
Chromosomal Location	17q23.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between PECAM1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between PECAM1 and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
20978210	Bladder Carcinoma	Inhibit immunity (T cell function)	Here we report that tumor and allograft rejection are significantly enhanced in CD31-deficient mice, which are also resistant to tolerance induction. We show that loss of CD31 interactions leads to enhanced primary clonal expansion, increased killing capacity, and diminished regulatory functions by T cells.
20630741	Follicular Lymphoma	Inhibit immunity	Increased CD31+ MVD correlated positively with the number of tumour infiltrating MCs and CD34+ vessels, and negatively with the outcome. Overall survival and progression-free survival were significantly better among patients with low CD31+ MVDs. Consistent with the immunohistochemical data, high CD31/PECAM1 mRNA levels were associated with adverse outcome.
25092771	colon carcinoma	Promote immunity	This combination therapy also increased TILs, including tumor antigen-specific CD8 T cells, and elevated the expression of activation markers FAS-L, CXCL-9, CD31, and CD105 in MDSCs and TAMs, leading to reduced tumor volumes and an increase in the number of tumor-free animals.

Summary
Symbol	PECAM1
Name	platelet/endothelial cell adhesion molecule 1
Aliases	CD31; CD31 antigen; platelet/endothelial cell adhesion molecule; CD31/EndoCAM; GPIIA'; PECA1; PECAM-1; endoC ......
Chromosomal Location	17q23.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of PECAM1 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	PECAM1
Name	platelet/endothelial cell adhesion molecule 1
Aliases	CD31; CD31 antigen; platelet/endothelial cell adhesion molecule; CD31/EndoCAM; GPIIA'; PECA1; PECAM-1; endoC ......
Chromosomal Location	17q23.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of PECAM1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.651	0.0601
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.538	0.761
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.73	0.562
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.125	0.729
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.304	0.881
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.097	0.969
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.287	0.543
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.434	0.788
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.08	0.965
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0	1
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0	1
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.298	0.0187

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of PECAM1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	7.4	7.4	0.0709
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	7.4	7.4	0.096
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	1

Summary
Symbol	PECAM1
Name	platelet/endothelial cell adhesion molecule 1
Aliases	CD31; CD31 antigen; platelet/endothelial cell adhesion molecule; CD31/EndoCAM; GPIIA'; PECA1; PECAM-1; endoC ......
Chromosomal Location	17q23.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of PECAM1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	PECAM1
Name	platelet/endothelial cell adhesion molecule 1
Aliases	CD31; CD31 antigen; platelet/endothelial cell adhesion molecule; CD31/EndoCAM; GPIIA'; PECA1; PECAM-1; endoC ......
Chromosomal Location	17q23.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of PECAM1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by PECAM1. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	PECAM1
Name	platelet/endothelial cell adhesion molecule 1
Aliases	CD31; CD31 antigen; platelet/endothelial cell adhesion molecule; CD31/EndoCAM; GPIIA'; PECA1; PECAM-1; endoC ......
Chromosomal Location	17q23.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of PECAM1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	PECAM1
Name	platelet/endothelial cell adhesion molecule 1
Aliases	CD31; CD31 antigen; platelet/endothelial cell adhesion molecule; CD31/EndoCAM; GPIIA'; PECA1; PECAM-1; endoC ......
Chromosomal Location	17q23.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of PECAM1 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	PECAM1
Name	platelet/endothelial cell adhesion molecule 1
Aliases	CD31; CD31 antigen; platelet/endothelial cell adhesion molecule; CD31/EndoCAM; GPIIA'; PECA1; PECAM-1; endoC ......
Chromosomal Location	17q23.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between PECAM1 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	PECAM1
Name	platelet/endothelial cell adhesion molecule 1
Aliases	CD31; CD31 antigen; platelet/endothelial cell adhesion molecule; CD31/EndoCAM; GPIIA'; PECA1; PECAM-1; endoC ......
Chromosomal Location	17q23.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting PECAM1 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse PECAM1